Radhika Tripuraneni, MD Mph
About Radhika Tripuraneni, MD Mph
Radhika Tripuraneni, MD MPH, serves as the Chief Development Officer at Prothena Corporation plc, where she has worked since 2018. She has a diverse background in medical affairs, health policy, and economics, with previous roles at notable companies including Sanofi Genzyme and Gilead Sciences.
Work at Prothena
Radhika Tripuraneni serves as the Chief Development Officer (CDO) at Prothena Corporation plc, a position she has held since 2018. In this role, she oversees development operations and strategic initiatives within the company. Prior to her current role, she worked as Vice President of Medical Affairs & Development Operations at Prothena for eight months. Her experience in the biotechnology sector contributes to the company's focus on developing therapies for neurodegenerative diseases.
Education and Expertise
Radhika Tripuraneni holds multiple degrees, including a Doctor of Medicine (MD) from the University of Missouri-Kansas City and a Master of Public Health (MPH) in Health Policy & Management from Harvard University. She also earned a Bachelor of Business Administration (BBA) and a Bachelor of Liberal Arts (BLA) from the University of Missouri-Kansas City. Her educational background equips her with a strong foundation in health policy, health economics, and strategic scientific communication.
Background
Radhika Tripuraneni has extensive experience in the pharmaceutical and biotechnology industries. She began her career as a Research Fellow at the National Institutes of Health (NIH) and has held various leadership positions. She worked at Sanofi Genzyme as Associate Director of Corporate Development and later as Global Medical Director for Gaucher & MPS Disease. Her career also includes roles at Gilead Sciences, MyoKardia, Synageva BioPharma Corp., and Alexion Pharmaceuticals, where she focused on medical affairs and development.
Achievements
Throughout her career, Radhika Tripuraneni has developed expertise in health policy, health economics, and strategic scientific communication. She has experience in pricing models, which involves creating strategies for healthcare product pricing. Her leadership roles in various organizations have contributed to advancements in medical affairs and development operations, particularly in the areas of cardiovascular health and rare diseases.